Models

Target selectivity, therapeutic index, biomarker strategy, clinical & regulatory signals.

Unmet need and whitespace penalized by competitive saturation and consensus attention.

Literature, trial, regulatory, and BioNeMo signal coverage blend.

Distance to 23 prior ADC failure archetypes via weighted feature vectors.

Pathway proximity, druggability, and internalization plausibility (API-ready).

Top-level ranking signal combining all models minus failure penalty.

Thesis stress test under uncertainty with sensitivity tornado and scenarios.

Probabilistic development-state inference and regime-shift detection.